TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7911009
Drug: Acrivastine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acrivastine (8 mg)
Study: 24817035
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg)
Study: 26905469
Drug: Antenatal corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroid administration before elective caesarean section at term
Study: 21219436
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus insulin injection
Study: 21303634
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin infusion
Study: 16835281
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg/month)
Study: 12830733
Drug: Novel targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel targeted therapies
Study: 12830733
Drug: Nonspecific cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific cytotoxic chemotherapeutic agents
Study: 9124056
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol (0.1 mg/kg per dose, four times a day)
Study: 9124056
Drug: MDI salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDI salbutamol (200 micrograms per dose, every 3 h)
Study: 9124056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no bronchodilator therapy)
Study: 7908144
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate nasal spray (BDP)
Study: 7908144
Drug: Placebo/azelastine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/azelastine treatment
Study: 3223752
Drug: Pivmecillinam (perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam (perioperative treatment from the evening before the operation to the day after removal of the catheter)
Study: 3223752
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no perioperative treatment)
Study: 25308771
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride 50 mg/day for 6 weeks
Study: 25910064
Drug: Low-volume preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume preparation (15 mg bisacodyl plus 2 L polyethylene glycol [PEG] solution)
Study: 25910064
Drug: High-volume preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume preparation (4 L PEG)
Study: 12881209
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (1,000 mg) and vitamin E (800 IU) daily for 6 months
Study: 1914560
Drug: Fluid gain
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid gain less than 1 L by 36 hours
Study: 1914560
Drug: Fluid gain
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid gain greater than 1 L by 36 hours
Study: 1914560
Drug: Median duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median duration of days on the ventilator, ICU days, and days of hospitalization for less than 1 L fluid gain
Study: 6114721
Drug: Follow-up interviews
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up interviews at one and six months after treatment
Study: 30501950
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Ticagrelor 90 mg twice per day
Study: 30501950
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Clopidogrel 75 mg once per day
Study: 21145828
Drug: High-dose ursodesoxycholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodesoxycholic acid (HD-UDCA) 28-35 mg/kg per day
Study: 21145828
Drug: High-dose ursodesoxycholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodesoxycholic acid (HD-UDCA)
Study: 15088420
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg, oral single dose)
Study: 15088420
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg, oral single dose)
Study: 8201382
Drug: 131I‐mAbF19 administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I‐mAbF19 administered intravenously
Study: 28899715
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D) supplementation (100,000 loading dose followed by 4000 IU daily for 16 weeks)
Study: 23146065
Drug: Topical acetyl
Normalized name: Acetyl sulfisoxazole
DrugBank: Acetyl sulfisoxazole (DB14033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acetyl hexapeptide-8 (AH8)
Study: 12635780
Drug: Palatal plate
Normalized name: malate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palatal plate therapy (PPG)
Study: 1825278
Drug: Effective nursing
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective nursing intervention, antifungal medication, and a moisture barrier ointment
Study: 6210180
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dimetophrine tablets
Study: 6210180
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg midodrine tablets
Study: 30880286
Drug: Polysomnographic titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysomnographic titration (PSG)
Study: 30880286
Drug: Control (daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (daytime titration followed by sham PSG)
Study: 22948494
Drug: Rectal/nasopharyngeal trumpet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal/nasopharyngeal trumpet
Study: 21930596
Drug: IH with
Normalized name: trenbolone acetate 80 mg / estradiol 8 mg / tylosin tartrate 29 mg SUBCUTANEOUS IMPLANT [Component TE-IH With Tylan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IH with placebo medication
Study: 20625082
Drug: IH with
Normalized name: trenbolone acetate 80 mg / estradiol 8 mg / tylosin tartrate 29 mg SUBCUTANEOUS IMPLANT [Component TE-IH With Tylan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IH with losartan (type I angiotensin II receptor antagonist)
Study: 18346622
Drug: Reflexology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology treatment (40 min, once per week for six weeks)
Study: 18346622
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (40 min, once per week for six weeks)
Study: 18346622
Drug: Reflexology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reflexology treatment
Study: 15981065
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with polyethylene glycol (PEG group)
Study: 12521651
Drug: Continuous group
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous group (168 days without a pill-free interval)
Study: 2694742
Drug: Clindamycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (single preoperative dose)
Study: 786668
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine (100 mg)
Study: 786668
Drug: Oral meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meperidine (150 mg)
Study: 786668
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of intramuscular dose (mg/kg)
Study: 28579415
Drug: Elagolix alone
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix alone (100 mg BID, 200 mg BID, 300 mg BID, 400 mg QD, 600 mg QD)
Study: 28579415
Drug: Elagolix with
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix with add-back therapy (200 mg BID plus continuous low-dose E2 0.5 mg/norethindrone acetate 0.1 mg or elagolix 300 mg BID plus E2 1 mg continuously and cyclical P 200 mg)
Study: 25196993
Drug: Blosozumab 270
Normalized name: Blosozumab
DrugBank: Blosozumab (DB12560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blosozumab 270 mg every 2 weeks (Q2W)
Study: 25196993
Drug: Blosozumab 180
Normalized name: Blosozumab
DrugBank: Blosozumab (DB12560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blosozumab 180 mg every 2 weeks (Q2W)
Study: 23820652
Drug: Periprostatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic nerve blockade in addition to intrarectal lidocaine gel
Study: 19752608
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel
Study: 19032723
Drug: Ibudilast 30
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ibudilast 30 mg single administration followed by 30 mg b.i.d. for 14 days
Study: 7629954
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg daily)
Study: 11281167
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid emulsion (1.6 ml)
Study: 11281167
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid emulsion (3.2 ml)
Study: 11281167
Drug: Control emulsion
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control emulsion (0 ml oleic acid)
Study: 11281167
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid treatment
Study: 8140906
Drug: Mianserin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (daily dose 20-60 mg)
Study: 2849539
Drug: NaHCO3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaHCO3 treatment (2.9 mmol of NaHCO3.kg‐1 body weight)
Study: 2849539
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (17 mmol of NaCl)
Study: 2849539
Drug: No-drink treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drink treatment
Study: 560645
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tyramine
Study: 30178577
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral aspirin
Study: 27846743
Drug: Enalapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ACE inhibitor, 5 mg od)
Study: 27846743
Drug: Candesartan (AT1R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (AT1R antagonist, 8 mg od)
Study: 19365151
Drug: ABIO-08/01 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABIO-08/01 (10 mg)
Study: 19365151
Drug: ABIO-08/01 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABIO-08/01 (20 mg)
Study: 19365151
Drug: ABIO-08/01 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABIO-08/01 (40 mg)
Study: 17498886
Drug: Goserelin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin and flutamide for 2 months before and during radiation therapy (RT) +/− 24 months of goserelin (long-term androgen deprivation plus radiation [LTAD-RT])
Study: 15161117
Drug: rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rofecoxib 50 mg once daily
Study: 7626858
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose chemotherapy
Study: 7905523
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine (1000 mg every 8 h and 100 mg every 8 h, respectively)
Study: 7905523
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with N-butyl-deoxynojirimycin (SC-48334) and zidovudine
Study: 2594133
Drug: Intraventricular injection
Normalized name: Brineura 150 MG in 5 mL Intraventricular Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular injection of morphine
Study: 2594133
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of morphine
Study: 31670776
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block (subcutaneous)
Study: 30951210
Drug: Achieving at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieving at least a 1-level reduction in WHO risk drinking levels by the end of treatment
Study: 30951210
Drug: Achieving at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achieving at least a 2-level reduction in WHO risk drinking levels by the end of treatment
Study: 29279933
Drug: Cefazolin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (1000 mg intravenous preoperative dose)
Study: 29279933
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% sodium chloride intravenous preoperative dose)
Study: 25925742
Drug: Gold standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold standard programme for alcohol cessation intervention, including structured patient education, weekly intervention meetings, thiamine and B-vitamins, alcohol withdrawal prophylaxis, and disulfiram for abstinence support.
Study: 24393553
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg linagliptin once daily
Study: 24393553
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg linagliptin
Study: 20680276
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (closed reduction followed by fragment excision)
Study: 20680276
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (closed reduction)
Study: 16374142
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day after 12 months
Study: 1410747
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of mepivacaine 2% at craniostate fixation points
Study: 2866291
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (2 litres of 0.9% saline over 1 hour)
Study: 29172800
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire (Group A)
Study: 29172800
Drug: GP-administered questionnaire
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP-administered questionnaire (Group B)
Study: 28304291
Drug: Insulin Resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Resistance (top HOMA-IR quartile)
Study: 25899029
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (0.15 mmol/kg body weight/h)
Study: 25899029
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no sodium bicarbonate infusion)
Study: 20184225
Drug: Triflusal capsules
Normalized name: triflusal
DrugBank: Triflusal (DB08814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal capsules (300 mg x 2)
Study: 15893540
Drug: Marimastat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat (5 mg)
Study: 12849799
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (group 1 and group 2)
Study: 1768561
Drug: Levodopa (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (125 mg, three oral doses at 2-hour intervals)
Study: 1768561
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of soluble paracetamol with levodopa
Study: 1768561
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of radiolabelled DTPA with levodopa
Study: 24326003
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg/day
Study: 25455721
Drug: 100,000 units
Normalized name: nystatin 100,000 units vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100,000 units oral vitamin D3 every 2 months for 6 months
Study: 22773397
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefazolin systemically 10 minutes before tourniquet inflation
Study: 22773397
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefazolin intraosseously in 200 mL of normal saline after tourniquet inflation
Study: 12875066
Drug: Anti-epilepsy capsules
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-epilepsy capsules
Study: 10868558
Drug: Loratadine syrup
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine syrup (5 mg, 1 mg/mL)
Study: 3080865
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (IV)
Study: 29114936
Drug: Simple training
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple training comprising four basic, single‐molecule substances
Study: 27068399
Drug: Atazanavir/ritonavir (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (300/100 mg)
Study: 27068399
Drug: Darunavir/ritonavir (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir (800/100 mg)
Study: 20105163
Drug: GR1 (1‐hour,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR1 (1‐hour, 50‐g glucose screen +/‐ 3‐hour, 100‐g OGTT)
Study: 20105163
Drug: GR2 (50‐g
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR2 (50‐g GS +/‐ 2‐hour, 75‐g OGTT)
Study: 20105163
Drug: GR3 (2‐hour,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR3 (2‐hour, 75‐g OGTT)
Study: 12574898
Drug: Colchicine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (1.5 mg/day) for 1 month
Study: 1731034
Drug: Daily maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily maintenance sodium (3 to 4 mEq of sodium per kilogram per day)
Study: 1731034
Drug: Salt restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt restriction (no sodium supplement other than with treatments such as transfusion)
Study: 6376301
Drug: Tetrachlorodecaoxide (TCDO)
Normalized name: Tetrachlorodecaoxide
DrugBank: Tetrachlorodecaoxide (DB05389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrachlorodecaoxide (TCDO) in a water solution containing glycerin
Study: 29450890
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1600 mg once daily
Study: 29450890
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1200 mg once daily
Study: 22945623
Drug: 1000‐mg naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000‐mg naltrexone implant and oral placebo (NI+OP group; 102 patients)
Study: 22945623
Drug: Placebo implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implant and 50‐mg oral naltrexone hydrochloride (PI+ON group; 102 patients)
Study: 22945623
Drug: Placebo implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implant and oral placebo (PI+OP group; 102 patients)
Study: 10085276
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg SQV/200 mg RTV
Study: 10085276
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg SQV
Study: 27085785
Drug: Alanine aminotransferase
Normalized name: Alanine aminotransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alanine aminotransferase (ALT) levels, adjusted for every standard deviation increase (13.2 U/L)
Study: 27085785
Drug: γ-glutamyl transferase
Normalized name: 5-L-Glutamyl-L-cysteinylglycine
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-glutamyl transferase (GGT) >70 U/L
Study: 27085785
Drug: GGT >70
Approvals — FDA: no, EMA: no, PMDA: no
Description: GGT >70 U/L
Study: 19843837
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with at least one unexplained medication discrepancy
Study: 19843837
Drug: Patients prescribed
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients prescribed 5 or more drugs at discharge from the ED
Study: 2216622
Drug: Single-dose surfactant
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose surfactant (100 mg/kg of bovine surfactant)
Study: 2216622
Drug: Multiple-dose surfactant
Normalized name: surfactant protein-D homotrimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose surfactant (100 mg/kg of bovine surfactant, eligible for up to three additional doses)
Study: 30430605
Drug: Emricasan 25
Normalized name: Emricasán
DrugBank: Emricasan (DB05408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emricasan 25 mg twice daily
Study: 25468170
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of antibiotic treatment
Study: 25468170
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of antibiotic treatment
Study: 23321318
Drug: Telaprevir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telaprevir (750 mg every 8h) with PegIFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 48 weeks